Chris Blohm’s Post

Precision Oncology is a Growing Market … More Room for Blockbuster Sales 👉 Precision Oncology is a rapidly growing market with the potential to transform clinical practice. Advancements in science and medicine have highlighted that cancer is a disease of the genome, not just a specific anatomical location 👉  Moving treatments earlier in therapy could significantly enhance overall survival efficacy, a key driver in the evolution of precision oncology. Recent M&A activity in the field, such as Merck's acquisition of Harpoon Therapeutics and J&J's purchase of Ambrx Biopharma, emphasizes the industry's dynamism 👉 Despite its promising future, precision oncology encounters challenges in regulatory, reimbursement, and intellectual property domains. Structural hurdles also contribute to a competitive landscape. Stay tuned for more insights into this groundbreaking sector #PrecisionOncology #MedicalAdvancements #HealthcareIndustry #ClinicalInnovations #precisiononcology #targetedtherapy #cancertreatment #competitiveintelligence #marketintelligence #perspectives #eosintelligence #leadership #lifesciences #pharmaceuticals #management #consulting #marketing #marketresearch #oncologydrugs #oncology #biotech --------------------------------------------------------------------------------- Write to me at bhabesh.panigrahi@eos-intelligence to schedule a no-obligation consultation for a winning precision oncology treatment strategy

Day 2 at #ESMO2024 It's amazing to witness firsthand how the oncology landscape has transformed in the last few years. The drug development pipeline in oncology is evolving at an unprecedented pace, driven by advancements in precision medicine, immuno-oncology, and AI-driven clinical trials. What’s fascinating is how we’ve moved from a one-size-fits-all approach to personalized therapies targeting specific mutations and pathways. Immunotherapies and CAR-T therapies are showing remarkable promise, offering hope where there once was none. Furthermore, the integration of real-world evidence (RWE) is playing a pivotal role in shaping decisions on safety, efficacy, and patient outcomes. The energy here is palpable, and I’m excited to continue networking with like-minded professionals who are passionate about making a difference in oncology. #OncologyInnovation #PrecisionMedicine #Immunotherapy #RealWorldEvidence #Pharma #DrugDevelopment #PatientCentricity

Immunotherapies stole the spotlight at ESMO - European Society for Medical Oncology Congress 2024, but emerging critiques suggest a need for a new strategic narrative.   Despite celebrating a decade of life-saving breakthroughs, the conversation highlighted gaps in efficacy and accessibility, challenging the status quo of immunotherapy as a silver bullet.   Commetric's media analysis suggests that a strategic pivot towards multi-modal, personalised treatments could redefine the future of oncology, steering away from a one-size-fits-all approach.   For pharma PR and comms teams, it’s time to reposition immunotherapies as part of a holistic treatment strategy.   Read our full ESMO 2024 analysis by following the link in the comments 👇 to learn which pharma companies gained most media traction and how strategic media analysis can empower your comms strategy. #oncology #immunotherapry #corporatecommunications #publicrelations #pharma #ESMO24 Merck AstraZeneca Roche Pfizer Bristol Myers Squibb

Artificial intelligence (AI) is revolutionizing the field of oncology, delivering groundbreaking results from drug development to early cancer detection. By leveraging advanced AI technologies, the pharmaceutical and healthcare sectors are accelerating the development of cancer treatments, improving diagnostic accuracy, and ultimately offering better outcomes for patients. To know more details regarding how AI can transforn in the field of Oncology, click the below link and follow Maven Scientific Laboratories Pvt Ltd https://lnkd.in/gRcE2YbY #AIinOncology #CancerDetectionAI #DrugDevelopmentAI #CancerDiagnosticsAI #MachineLearningInOncology #AICancerTreatment #AIDrugDiscovery #OncologyAdvancements #PersonalizedCancerTherapy #AICancerResearch #PrecisionMedicine #CancerTherapies

📣We are delighted to announce a strategic collaboration with CTI Clinical Trial and Consulting Services, a renowned full-spectrum research services provider, to bolster oncology-focused consulting services. This partnership combines decades of expertise from both organizations in oncology drug discovery and development, leveraging Crown Bioscience’s preclinical and translational models and CTI’s well-established track record in the clinical and regulatory space. Customers will benefit from the combined expert guidance, supporting the transition of oncology compounds from discovery through early-phase global trials more rapidly and effectively. This alliance aims to determine the best and most expeditious path to the clinic, ensure long-term drug development success and growth, and accelerate the delivery of more oncology therapeutics to patients. Read the full release here ➡️https://hubs.la/Q02M2QsT0 #Biotech #Bioscience #Oncology #DrugDevelopment

The three-week countdown begins for the 9th Liquid Biopsy for Precision Oncology, returning to San Diego this February 18-20. If you've not seen the program yet, you can get your copy here: https://ter.li/swfu1g Who attends❓ 🔻 Biopharma professionals and academics passionate about advancing precision oncology 🔻 Experts looking to overcome challenges in biomarkers, ctDNA, MRD, and regulatory approvals What will you gain❓ 🔻 Exclusive insights from 40+ senior leader speakers, including experts from ORIC Pharma, Bristol Myers Squibb, GSK, and Genentech 🔻 Address critical challenges like MRD approvals, ctDNA analysis, ultra-sensitive assays, reimbursement strategies, and bioinformatics innovation 🔻 Explore cutting-edge data and case studies that will redefine your approach to cancer diagnostics and personalized treatment. When and where❓ 📅 February 18–20, 2025 📍 Hilton La Jolla Torrey Pines, San Diego, CA With a limited number of free* tickets for biopharma remaining, visit the website to read through T&Cs and secure your place: https://ter.li/5y92u4 #LiquidBiopsy #PrecisionMedicine #PrecisionOncology

🌍 2023 Clinical Trial Highlights 🌍 🏆 Leading CRO: A big round of applause for Nucleus Network, the most active Contract Research Organization (CRO) in 2023. Their dedication to advancing medical research is truly commendable! 🔬 Top Sponsors: In the realm of large- and mega-cap sponsors, Pfizer (NYSE:PFE) took the lead, closely followed by AstraZeneca (LON:AZN). Their commitment to innovation continues to drive progress in healthcare. 📊 Oncology's Dominance: Oncology trials once again dominated the global landscape, reflecting the ongoing urgency in combating cancer. Solid tumors and pain in the CNS were the top indications, highlighting key areas of focus for researchers. 🌐 Regional Insights: California shone as the epicenter of clinical trial activity in the US, while Russia and China led the charge in Europe and the rest of the world (ROW) respectively. 💡 Introducing Exigyn: As we navigate these dynamic trends, Exigyn stands out as the premier FP&A budgeting tool tailored for clinical trials. Empower your finance teams with Exigyn to streamline budgeting and maximize the impact of your research. www.exigyn.com Let's celebrate these milestones and continue to push the boundaries of medical research for a healthier future! #ClinicalTrials #NucleusNetwork #Pfizer #AstraZeneca #Oncology #SolidTumors #PainManagement #California #Russia #China #Exigyn #FPABudgeting #clinicalaccruals #clinicalbudgets

AstraZeneca and Stanford Medicine have entered into a strategic collaboration to accelerate drug discovery and development through AI and innovative science. This collaboration highlights our commitment to pioneering advancements across therapeutic areas, aiming to bring new, life-changing treatments to patients sooner.  Our joint projects will leverage Stanford's in-house expertise and our advanced AI capabilities to enhance our understanding of cancer biology and design more effective clinical trials. This combined effort offers a unique opportunity to integrate cutting-edge technology into pharmaceutical research, driving innovation and enhancing patient outcomes. I’m excited to see the transformative impact of our combined efforts on the future of oncology treatments and am hopeful that collaborations like these will help to deliver breakthroughs to patients in need.     #AstraZeneca #Oncology #AI #PharmaceuticalR&D #Innovation 

🚀 Leadership in Oncology and Beyond: Lessons from Pfizer’s Bold R&D Move Pfizer’s recent decision to appoint Dr. Chris Boshoff as the head of its Research & Development highlights the evolving landscape of oncology-focused innovation. Dr. Boshoff, with his extensive background in oncology and proven track record at Pfizer, is now tasked with driving the development of impactful breakthrough medicines. As a staffing firm committed to ensuring oncology clinical trials are monitored with ICH/GCP and industry-standard expertise, Lampgen Clinical Research is inspired by such leadership shifts. This decision reinforces the importance of deep therapeutic area expertise and the necessity for a strategic approach to advancing cancer research. While Pfizer faces investor pressure to align R&D investments with greater returns, Dr. Boshoff’s appointment underscores the critical role of consistency, vision, and strategic execution in navigating complex challenges in drug development. With a promising pipeline and a clear focus on transformational medicines, the potential for breakthroughs in oncology remains robust. At Lampgen, we are proud to play a role in advancing oncology research by partnering with organizations to deliver skilled CRAs who share this mission. Together, we can bring transformative therapies to patients in need. #OncologyResearch #ClinicalTrials #CancerResearch #ClinicalOperations #ICHGCP #OncologyInnovation #DrugDevelopment #CRAs #LampgenClinicalResearch #PharmaLeadership https://lnkd.in/eM3PUq7k

🌟 Unlock the Latest Insights into the c-MET Non-Small Cell Lung Cancer Market! 🌟 DelveInsight Business Research LLP's comprehensive market report delves into the evolving landscape of c-MET #NSCLC, exploring cutting-edge therapeutics, ongoing clinical trials, and emerging trends that are shaping the future of this space. The leading #CMETNSCLCCompanies are mentioned below:- 1. AbbVie 2. Janssen Inc. Research & Development 3. Beijing Pearl Biotechnology Limited Liability Company 4. Novartis 🔍 Key c-MET Non-Small Cell Lung Cancer Market Report Highlights: ✔ Market Dynamics ✔ #NSCLCTreatment Landscape ✔ Competitive Insights ✔ Growth Opportunities Stay ahead in understanding the advancements driving innovation in the c-MET #NSCLCMarket. 📖 Discover More @ https://lnkd.in/eWqnBmTH #LungCancer #NSCLC #cMET #DelveInsight #MarketReport #PharmaInsights #OncologyMarket #BiotechInnovation